Tags

Type your tag names separated by a space and hit enter

The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
BMC Urol. 2016 Jul 29; 16(1):45.BU

Abstract

BACKGROUND

Mirabegron is a β3-adrenoreceptor agonist developed for treatment of overactive bladder (OAB). α1-Adrenergic receptor blockers are effective for lower urinary tract symptoms (LUTS) in male patients. However, the efficacy of mirabegron additional treatment in elderly male patients with persistent male LUTS, especially in OAB after monotherapy with α1-adrenergic blockers, is not fully understood.

METHODS

This study was conducted in male LUTS patients who were ≥ 65 years of age and had persistent OAB symptoms, regardless of whether they took an α1-adrenergic receptor blocker orally. Before and 12 weeks after mirabegron additional therapy (50 mg once daily), we evaluated the efficacy of this treatment using the Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score (IPSS), and changes in the maximum flow rate (Qmax) and post-void residual urine volume (PVR). We evaluated patients overall and divided into two groups by age: young-old (from 65 to 74 years old) and old-old (from 75 to 84 years old).

RESULTS

Fifty men were enrolled in this study. Mirabegron additional therapy improved the total OABSS, total IPSS, and IPSS-quality of life (QOL) score. The voided volume (VV) and Qmax improved after treatment in patients overall. However, there was no significant change in PVR. The total OABSS, total IPSS, and IPSS-QOL score significantly improved in both of the young-old and old-old groups. However, a significant increasing of VV was detected in the young-old group. There were no significant differences in the Qmax or PVR in either group.

CONCLUSIONS

Mirabegron additional therapy was effective for male patients whose persistent LUTS and particularly OAB was not controlled with α1-adrenergic receptor blocker monotherapy, and mirabegron did not have negative effects on voiding function. Additionally, mirabegron additional therapy was considered effective regardless of patient age.

TRIAL REGISTRATION

Trial registration number (TRN) trial registration number (TRN) and date of registration: ISRCTN16759097 in July 8, 2016.

Authors+Show Affiliations

Department of Urology, Nagasaki University Graduate School of Biochemical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.Department of Urology, Nagasaki University Graduate School of Biochemical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. int.doc.miya@m3.dion.ne.jp.Department of Urology, Nagasaki University Graduate School of Biochemical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.Department of Urology, Nagasaki University Graduate School of Biochemical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.Department of Urology, Nagasaki University Graduate School of Biochemical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.Department of Urology, Nagasaki University Graduate School of Biochemical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.Department of Urology, Nagasaki University Graduate School of Biochemical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27473059

Citation

Matsuo, Tomohiro, et al. "The Efficacy of Mirabegron Additional Therapy for Lower Urinary Tract Symptoms After Treatment With Α1-adrenergic Receptor Blocker Monotherapy: Prospective Analysis of Elderly Men." BMC Urology, vol. 16, no. 1, 2016, p. 45.
Matsuo T, Miyata Y, Kakoki K, et al. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. BMC Urol. 2016;16(1):45.
Matsuo, T., Miyata, Y., Kakoki, K., Yuzuriha, M., Asai, A., Ohba, K., & Sakai, H. (2016). The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. BMC Urology, 16(1), 45. https://doi.org/10.1186/s12894-016-0165-3
Matsuo T, et al. The Efficacy of Mirabegron Additional Therapy for Lower Urinary Tract Symptoms After Treatment With Α1-adrenergic Receptor Blocker Monotherapy: Prospective Analysis of Elderly Men. BMC Urol. 2016 Jul 29;16(1):45. PubMed PMID: 27473059.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. AU - Matsuo,Tomohiro, AU - Miyata,Yasuyoshi, AU - Kakoki,Katsura, AU - Yuzuriha,Miki, AU - Asai,Akihiro, AU - Ohba,Kojiro, AU - Sakai,Hideki, Y1 - 2016/07/29/ PY - 2016/03/06/received PY - 2016/07/22/accepted PY - 2016/7/31/entrez PY - 2016/7/31/pubmed PY - 2017/3/1/medline KW - Elderly male KW - Mirabegron KW - Overactive bladder KW - α1-adrenergic blockers SP - 45 EP - 45 JF - BMC urology JO - BMC Urol VL - 16 IS - 1 N2 - BACKGROUND: Mirabegron is a β3-adrenoreceptor agonist developed for treatment of overactive bladder (OAB). α1-Adrenergic receptor blockers are effective for lower urinary tract symptoms (LUTS) in male patients. However, the efficacy of mirabegron additional treatment in elderly male patients with persistent male LUTS, especially in OAB after monotherapy with α1-adrenergic blockers, is not fully understood. METHODS: This study was conducted in male LUTS patients who were ≥ 65 years of age and had persistent OAB symptoms, regardless of whether they took an α1-adrenergic receptor blocker orally. Before and 12 weeks after mirabegron additional therapy (50 mg once daily), we evaluated the efficacy of this treatment using the Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score (IPSS), and changes in the maximum flow rate (Qmax) and post-void residual urine volume (PVR). We evaluated patients overall and divided into two groups by age: young-old (from 65 to 74 years old) and old-old (from 75 to 84 years old). RESULTS: Fifty men were enrolled in this study. Mirabegron additional therapy improved the total OABSS, total IPSS, and IPSS-quality of life (QOL) score. The voided volume (VV) and Qmax improved after treatment in patients overall. However, there was no significant change in PVR. The total OABSS, total IPSS, and IPSS-QOL score significantly improved in both of the young-old and old-old groups. However, a significant increasing of VV was detected in the young-old group. There were no significant differences in the Qmax or PVR in either group. CONCLUSIONS: Mirabegron additional therapy was effective for male patients whose persistent LUTS and particularly OAB was not controlled with α1-adrenergic receptor blocker monotherapy, and mirabegron did not have negative effects on voiding function. Additionally, mirabegron additional therapy was considered effective regardless of patient age. TRIAL REGISTRATION: Trial registration number (TRN) trial registration number (TRN) and date of registration: ISRCTN16759097 in July 8, 2016. SN - 1471-2490 UR - https://www.unboundmedicine.com/medline/citation/27473059/The_efficacy_of_mirabegron_additional_therapy_for_lower_urinary_tract_symptoms_after_treatment_with_α1_adrenergic_receptor_blocker_monotherapy:_prospective_analysis_of_elderly_men_ L2 - https://bmcurol.biomedcentral.com/articles/10.1186/s12894-016-0165-3 DB - PRIME DP - Unbound Medicine ER -